Press Releases

Conference Call and Webcast Today at 10:00 a.m. Eastern Time

MEDFORD, N.Y. , April 29, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announced today that, for the first time, its SURE CHECK® HIV 1/2 testing device will be made available in self-test kits in Europe .

Conference Call Scheduled for Thursday, May 7th at 10:00a.m. Eastern Time

Conference Call and Webcast Today at 10:00 a.m. Eastern

Conference Call Scheduled for Thursday, March 5th at 10:00a.m. Eastern Time

Only Combination Assay Approved by Brazil's ANVISA for Point-of-Care Detection of HIV and Syphilis

Chembio to Support the Bill & Melinda Gates Foundation Malaria Eradication Campaign

MEDFORD, N.Y., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK ® HIV 1/2 Assay,

MEDFORD, N.Y., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP ® Ebola and DPP ® Febrile Illness Assays.

MEDFORD, N.Y., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics Systems, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the appointment of Paul Lambotte, Ph.D., as Vice President, Product Development.